Microlocalization of lipophilic porphyrins: Non-toxic enhancers of boron neutron-capture therapy

Henry M. Smilowitz¹ *, Daniel N. Slatkin², Peggy L. Micca² & Michiko Miura² *

¹Department of Cell Biology, University of Connecticut Health Center, Farmington, Connecticut, and ²Biosciences Department, Brookhaven National Laboratory, Upton, New York, USA

Abstract

Purpose: To compare the macroscopic and microscopic distributions of the novel non-toxic lipophilic porphyrins copper (II) 5,10,15,20-tetrakis-(3-[1,2 dicarba-closo-dodecaboranyl]methoxyphenyl)-porphyrin (CuTCPH), potentially useful for boron neutron-capture therapy (BNCT), with those of its zinc fluorescent congener zinc (II) 5,10,15,20-tetrakis-(3-[1,2 dicarba-closo-dodecaboranyl]methoxyphenyl)-porphyrin (ZnTCPH) in tissues of tumor-bearing mice.

Materials and methods: ZnTCPH and CuTCPH were synthesized, then injected intraperitoneally (ip) into tumor-bearing mice. Macrophscopic biodistribution was assessed by determining average boron concentrations in tumor, blood, brain, skin, and liver using atomic-emission spectrometry. The euthanized mice and their vital organs were photographed first under an ultraviolet lamp and then under a bright fluorescent lamp. Thin sections of liver and tumor were analyzed by confocal fluorescence microscopy (CFM).

Results: ZnTCPH-injected, but not CuTCPH-injected mice bearing subcutaneous tumors showed fluorescence from liver, spleen and tumors. Macroscopic biodistributions of boron in various tissues were similar in mice whether injected with ZnTCPH or CuTCPH. CFM of unfixed liver sections showed cytoplasmic fluorescence from Kupffer cells in a periportal lobular distribution evenly throughout the liver. In the tumors studied, such fluorescence was also cytoplasmic but unlike liver fluorescence, was macroscopically heterogeneous.

Conclusion: ZnTCPH serves as a useful fluorescent experimental surrogate for CuTCPH to delineate its macroscopic and microscopic distributions in organs and tumors.

Keywords: Porphyrins, carborane, confocal microscopy, BNCT

Introduction

Boron neutron-capture therapy (BNCT) is a form of radiosurgery implemented by parenteral administration of one or more boron-rich agents (synthesized with > 95 atom % ¹⁰B; > 95% of boron atoms are ¹⁰B and 5% are ¹¹B) that accumulate preferentially in the tumor, followed by irradiation of the tumor-bearing zone with slow neutrons (Coderre and Morris 1999, Barth et al. 2012). In Japan, the USA, Argentina, and several European countries, BNCT has been used with watersoluble ¹⁰B-enriched agents, notably p-boronophenylalanine (BPA) and/or sodium mercaptoundecahydrododecaborane (BSH) to palliate several types of human malignancies (Haritz et al. 1994, Chanana et al. 1999, Joensuu et al. 2003, Henricksen et al. 2008, Yamamoto et al. 2008, Sköld et al. 2010, Kawabata et al. 2011a, Kankaanranta et al. 2012). Infusions of BPA in glioblastoma patients yielded average tumor boron concentrations up to 3–4 times greater than those concomitantly in the blood (Joel et al. 1997, Cruickshank et al. 2009). Average tumor boron concentrations achieved with nontoxic lipophilic porphyrins are generally one order of magnitude greater than those achievable with BPA or BSH (Miura et al. 1996, 1998, Renner et al. 2006). After intravenous (iv) injection, such porphyrins accumulate and remain for days at therapeutically relevant concentrations in several types of animal tumors. They also accumulate robustly in several normal organs, notably the liver, but are virtually excluded from normal brain tissues and are cleared from the blood (Miura et al. 1998, 2004). Copper (II) 5,10,15,20-tetrakis-[3-[1,2 dicarba-closo-dodecaboranyl]methoxyphenyl]-porphyrin (CuTCPH) (Miura et al. 2001) and its octabromo analogue, copper (II) 2,3,7,8,12,13,17,18-octabromo-5,10,15,20-tetrakis-[3-[1,2-dicarba-closo-dodecaboranyl]methoxyphenyl]-porphyrin, (CuTCPBr) (Miura et al. 2004, 2012) are lipophilic congeners that can deliver robust concentrations of boron to several subcutaneous (sc) malignancies in mice with minimal toxicity. The subcutaneous (sc) murine EMT-6 mammary carcinoma has been palliated effectively by CuTCPH-based BNCT (Miura et al. 2001) and by CuTCPBr-enhanced X-ray radiotherapy (Miura et al. 2012). CuTCPBr or CuTCPH could also be used to image tumors noninvasively by labeling with ⁶⁷Cu for single-photon emission computed tomography (SPECT) or with ⁶⁸Cu for positron-emission tomography (PET). The...
former may also be employed for tissue-localization studies by autoradiography using dental X-ray films (M. Miura, unpublished observations).

The microdistribution of a $^{10}$B carrier is a major determinant of its effectiveness for BNCT; $^{10}$B is roughly three-fold more efficient in the nucleus than in the cytoplasm (Gabel et al. 1987). The macrodistributions of a number of water-soluble porphyrins that localize in tumors of rodents have been studied previously (Ozawa et al. 2005, Fabris et al. 2007) and the microlocalization of a water-soluble porphyrin was studied in vitro (Fabris et al. 2007), but to our knowledge the microlocalization of a boron-containing lipophilic porphyrin in any tumor has not been reported.

In order to study microlocalization properties of non-fluorescent CuTCPH by confocal fluorescence microscopy (CFM) of tissues in vivo, we synthesized a fluorescent congeners by replacing the copper (II) with zinc (II) to form zinc (II) 5,10,15,20-tetrakis-(3-[1,2 dicarba-closo-dodecaboranyl] methoxyphenyl)-porphyrin (ZnTCPH); zinc (II) porphyrins are fluorescent and copper (II) porphyrins are not, due mainly to the differences between the number of d electrons of those metals (Hopf and Whitten 1975). We then investigated its cellular and subcellular distributions in tumors and livers from mice using CFM, a technique employed for analogous studies related to photodynamic therapy (PDT) (Woodburn et al. 1991). Skin photosensitization by ZnTCPH contraindicates its clinical use, but CuTCPH merits study as a candidate enhancer of clinical boron neutron-capture therapy. It is possible that CFM information from ZnTCPH employed here as a fluorescent surrogate for CuTCPH in pre-clinical investigations might better enable treatment planning for pre-clinical studies of CuTCPH-mediated BNCT.

Materials and methods

Chemistry

All chemicals used for the synthesis of porphyrins and their formulations were purchased from Sigma-Aldrich (St Louis, MO, USA). CuTCPH was synthesized as described (Miura et al. 2001). Briefly, Cu (II) acetate (~1.5 mole equivalent) in methanol was added into a solution of free base porphyrin in dichloromethane for ~1 h at ambient temperature and monitored by optical spectroscopy (Carey 50 Spectrophotometer, Varian Inc., Palo Alto, CA, USA). The product was diluted with dichloromethane, washed with water, its solvents evaporated, and the residue purified by flash chromatography using silica and 1:1 hexanes:dichloromethane as eluent. Substitution of Zn (II) acetate for Cu (II) acetate in the same procedure yielded ZnTCPH. These metalloporphyrins were generally obtained in >90% yield from the free-base starting material.

Preparation of porphyrin solution for injection

A ~3 milligram (mg)/milliliter (ml) porphyrin solution in 9% Cremophor EL (CRM) (currently called Kalliphor EL, BASF Corp., Ludwigshafen, Germany) and 18% propylene glycol (PRG) was prepared by dissolving the porphyrin in tetrahydrofuran (THF) (1.5% of the total volume), then heating the solution at 40°C for ~15 min. CRM (9% of total volume) was added and the mixture was heated to 60°C for 2 h, evaporating virtually all the THF. After cooling to room temperature, PRG (18% of total volume) was added, followed by dropwise addition of saline (71.5% of total volume) with rapid stirring. The resultant formulation, a CRM/PRG emulsion, was degassed by stirring under vacuum (~30 mm Hg) for 30–60 min then filtered (Millipore, 8 μm, Billerica, MA, USA) (Zuk et al. 1994, Miura et al. 2001). The CRM excipient used for these studies is stable, non-toxic and effects high delivery of porphyrin to tumors in vivo. It has been used by us for many years for pre-clinical studies of our lipophilic porphyrins. A more recently developed formulation consisting of 2% purified Cremophor EL (ELP), 1% Tween 80, 5% ethanol and 2.2% PEG 400, designated the CTEP formulation (Miura et al. 2012), was not available when these studies were performed.

Tumor models

One human and two murine tumor cell lines were grown in Dulbecco’s Modified Eagle Medium (DMEM)-enriched medium with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine. The two murine malignancies were studied by CFM as sc leg tumors. The EMT-6 mouse mammary tumor cell line kindly provided by Dr Rockwell (Rockwell et al. 1972) was initially grown sc to at least 100 mm$^3$ in the dorsal thorax of isogeneic female BALB/c mice (20–25 g, Taconic Farms, Germantown, NY, USA). Freshly removed primary tumor tissue was then minced in saline and <0.5 mm fragments were implanted sc in the legs of female BALB/c mice through an 18-gauge trocar (Miura et al. 2001). Murine SCCVII squamous cell carcinoma cells (5 × 10$^5$) (kindly provided by Prof. J. Martin Brown, Stanford University) were grown similarly in the dorsal thorax and implanted sc in the legs of female isogeneic C3H mice (Taconic Farms, body weight 20–25 g) (Fu et al. 1984, Miura et al. 2004). To study the correlation between the copper and zinc analogues, biodistribution studies were carried out in mice with dorsal thoracic sc tumors (Table I). For human malignant glioma U373 cells, 5 × 10$^6$ cells (de Ridder et al. 1987) were implanted sc into the dorsal thorax of each recipient SCID/beige mouse (Taconic Farms, 20–25 g, Taconic Farms, Germantown, NY, USA). Tumors were grown similarly in the dorsal thorax of isogeneic female BALB/c mice (20–25 g, Taconic Farms, Germantown, NY, USA). Tumors were studied by CFM as sc leg tumors. The EMT-6 mouse mammary tumor cell line kindly provided by Dr Rockwell (Rockwell et al. 1972) was initially grown sc to at least 100 mm$^3$ in the dorsal thorax of isogeneic female BALB/c mice (20–25 g, Taconic Farms, Germantown, NY, USA). Freshly removed primary tumor tissue was then minced in saline and <0.5 mm fragments were implanted sc in the legs of female BALB/c mice through an 18-gauge trocar (Miura et al. 2001). Murine SCCVII squamous cell carcinoma cells (5 × 10$^5$) (kindly provided by Prof. J. Martin Brown, Stanford University) were grown similarly in the dorsal thorax and implanted sc in the legs of female isogeneic C3H mice (Taconic Farms, body weight 20–25 g) (Fu et al. 1984, Miura et al. 2004). To study the correlation between the copper and zinc analogues, biodistribution studies were carried out in mice with dorsal thoracic sc tumors (Table I). For human malignant glioma U373 cells, 5 × 10$^6$ cells (de Ridder et al. 1987) were implanted sc into the dorsal thorax of each recipient SCID/beige mouse (Taconic Farms) then studied when the tumors grew to at least 100 mm$^3$. All protocols involving the use of mice were approved by the Brookhaven National Laboratory (BNL) and the University of Connecticut Health Center (UCHC) animal care committees.

Table I. Average concentrations (and standard deviations) of boron (μg/g) in various tissues from BALB/c mice bearing subcutaneous EMT-6 mammary carcinomas, which were given either CuTCPH at 180 mg/kgbw or ZnTCPH at 210 mg/kgbw in 6 ip injections given over a period of 2 days then euthanized 2 or 4 days after the last injection.

<table>
<thead>
<tr>
<th>Porphyrin</th>
<th>CuTCPH</th>
<th>ZnTCPH</th>
<th>CuTCPH</th>
<th>ZnTCPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time after last injection (d)</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Number of mice</td>
<td>7</td>
<td>5</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Tumor boron (μg/g)</td>
<td>62 ± 10</td>
<td>137 ± 59</td>
<td>71 ± 19</td>
<td>84 ± 21</td>
</tr>
<tr>
<td>Blood boron (μg/g)</td>
<td>0 ± 0.1</td>
<td>0.1 ± 0.1</td>
<td>0.3 ± 0.1</td>
<td>0.1 ± 0.1</td>
</tr>
<tr>
<td>Cerebrum boron (μg/g)</td>
<td>0.2 ± 0.1</td>
<td>0.2 ± 0.1</td>
<td>0.7 ± 0.3</td>
<td>0.3 ± 0.1</td>
</tr>
<tr>
<td>Pinna (mainly skin) boron (μg/g)</td>
<td>8.4 ± 2.1</td>
<td>7.2 ± 2.8</td>
<td>14.2 ± 2.6</td>
<td>5.9 ± 2.4</td>
</tr>
<tr>
<td>Liver boron (μg/g)</td>
<td>562 ± 79</td>
<td>555 ± 139</td>
<td>534 ± 124</td>
<td>501 ± 72</td>
</tr>
<tr>
<td>Tumor mass (mg)</td>
<td>405 ± 151</td>
<td>145 ± 93</td>
<td>335 ± 157</td>
<td>344 ± 174</td>
</tr>
</tbody>
</table>
Porphyrin administration

Each porphyrin was delivered in six injections: Three intraperitoneal (ip) injections at 4 h intervals over 8 h on two successive days. Injections of CuTCPH or ZnTCPH were begun in BALB/c mice when their EMT-6 tumors weighed ~100 mg (10–11 days after implantation): A total of 180–210 mg porphyrin/kilogram body weight (kgbw) was delivered in 0.01 ml/gram body weight (gbw)/injection. Similar injections were begun in SCID mice 32 days after their U373 tumors had been initiated (180–190 mg porphyrin/kgbw) and in C3H mice bearing ~100 mg SCCVII tumors (10 days post implantation, 350 mg porphyrin/kgbw). Mice were euthanized 2 or 4 days after the last injection then promptly necropsied. One mouse each from the CuTCPH and ZnTCPH groups was photographed in fluorescent and long-wave ‘black’ ultraviolet light before necropsy (Figure 1).

Histology

Cryotome (Thermo Scientific, Waltham, MA, USA) sections (~5 micrometer [μm]- or ~25 μm-thick) were prepared from tumor and liver tissue samples that had been snap-frozen in liquid-nitrogen-cooled isopentane immediately after euthanasia. Adjacent cryotome slices (~5 μm-thick) were mounted on 1″×3″ borosilicate glass microscope slides (Fisher Scientific, Pittsburgh, PA, USA) and either air-dried then frozen at about −20°C or formalin-fixed. Some of the former were counterstained with quinolinium, 4-[3-(3-methyl-2 (3H)-benzothiazolylidene)-1-propenyl]-1-[3-(trimethylammonio)propyl]-diiodide (TO-PRO-3; Molecular Probes, Eugene, Oregon, USA) or 3,3’dioctadecycloxacarbocyanine perchlorate (DiO), Molecular Probes, Eugene, Oregon) to highlight cell nuclei or cell cytoplasm, respectively. The latter were stained with hematoxylin/eosin at ambient room temperature.

Confocal fluorescence microscopy (CFM)

Cryotome sections of snap-frozen liver and tumor specimens were thawed on microscope slides, immediately overlaid with 2–5 μl phosphate-buffered saline (PBS), then sealed watertight with petroleum jelly under a borosilicate glass coverslip. Within minutes thereafter they were illuminated at 468 or 488 nanometer (nm) to image ZnTCPH’s red fluorescence at 575–640 nm by CFM using either a model Zeiss LSM 410 or 510 instrument (Thornwood, NY, USA). To assess the sensitivity of the CFM system, normal BALB/c mice were injected ip as described above using progressively larger total doses of ZnTCPH (44, 87, or 174 mg/kgbw) and euthanized 2 days after the last injection. Cryotome sections of their livers (with correspondingly higher average concentrations of boron: 38, 89, or 168 μg/g) were examined by CFM without counterstaining at low magnification (Example: Figure 2, Frame A, average boron concentration, 38 μg/g wet liver). To visualize nuclei, a 1 mM stock solution of TO-PRO-3 was diluted 1:1000 in PBS then applied to the

Figure 1. Mice with bilateral subcutaneous EMT-6 thigh tumors (A & C) and their organs (B & D) two days after the last of six intraperitoneal injections over two days of CuTCPH (left side of each frame) or ZnTCPH (right side of each frame): Illumination by standard ‘fluorescent’ ceiling light (A & B); illumination by long-wave ultraviolet (‘black’) light (C & D). The 11 pairs of letters, a, a’ through k, k’, label the left and right EMT-6 thigh tumors, brain, thymus, heart, spleen, duodenum, lungs, liver, and left and right kidneys from the CuTCPH-injected (left) and ZnTCPH-injected (right) mouse, respectively.
thawed tissue section, which was illuminated at 633 nm. Its ‘far-red’ fluorescence was detected with a long-pass 650 nm filter and instantly computer-converted to blue in the image to avoid confusion with near-red ZnTCPH fluorescence. To visualize cytoplasm, a stock ethanolic solution (0.5 mM) of the lipophilic membrane dye DiO was diluted 1:100 in phosphate buffer solution (PBS), then applied to the thawed section; it was excited at 484 nm and its 501 nm fluorescence showed cells with green cytoplasmic features.

Boron analyses
Tissue samples (50–130 mg) were digested at 60°C with sulfuric acid:nitric acid (1:1). Triton X-100 and water were added to give final concentrations of ~50 mg tissue/ml with 15% total acid v/v and 5% Triton X-100 volume per volume (v/v). Direct current plasma atomic-emission spectroscopy (DCP-AES) with a detection limit of 0.1 μg B/ml sample homogenate was implemented with an Applied Research Laboratories (ARL) Fisons Model SS-7 instrument (Thermo-Optek, Franklin, MA, USA) (Barth et al. 1991).

Results
Visual biodistributions of CuTCPH and ZnTCPH in mice bearing EMT-6 tumors
Nominally similar doses of CuTCPH (190 mg/kgbw) or ZnTCPH (175 mg/kgbw) were injected ip into two BALB/c mice bearing bilateral EMT-6 thigh tumors. Four days after administration, the mice were euthanized and then photographed while illuminated, first by long-wave ultraviolet (‘black’) light (Figure 1C & D) for ~1 min, then under a standard indoor office ‘fluorescent’ ceiling light fixture for ~1 sec (Figure 1A & B). Red fluorescence was seen only from the ZnTCPH-injected mouse (Figure 1D, right); most organs from the CuTCPH-injected mouse appeared similar to those from the non-injected mice. In the absence of red fluorescence, green autofluorescence was seen from all tissues except the lungs (Figure 1D, right and left). DCP-AES assays showed higher concentrations of boron in liver and tumor samples removed from the CuTCPH-injected (Figure 1, left) mouse (~513 and ~98 μgB/g, respectively) than from the ZnTCPH-injected (Figure 1, right) mouse (~185 and ~34 μgB/g, respectively). This supports our hypothesis that CuTCPH, non-fluorescent in vitro, probably is not converted to a fluorescent metabolite in vivo.

Macroscopic biodistribution of boron in mice
Mice injected with similar doses of CuTCPH and ZnTCPH generally showed good correspondence in median boron concentrations, 68 vs. 88 μg B/g, respectively, in subcutaneous EMT-6 tumors of comparable median weights, 311 vs. 327 mg, respectively (Table I). When tumor sizes were dissimilar, average boron concentrations tended to be higher in the smaller tumors, as seen previously (Miura et al. 1992). Average liver boron levels, indicators of the concomitant bio availability of injected porphyrins to other tissues, were higher than those in tumor and changed in parallel with the latter from day 2–4 (Table I).

Microscopic distribution of ZnTCPH in liver
Fluorescence of ZnTCPH was barely detected by CFM in non-counterstained sections of livers with average macroscopic boron concentrations of 38 μg/g liver, which is therefore our rough estimate of the limit of detection in tissues of porphyrin-linked boron using the confocal microscopy technique described above (Figure 2A). Abundant cytoplasmic fluorescence from DiO-counterstained sections of snap-frozen liver specimens is depicted at higher magnification (Figure 2B). Its microscopic histological distribution suggests that most of the ZnTCPH in the liver is in hepatic macrophages (Kupff er cells), mainly in the perportal zones of the liver, with fluorescence practically absent from Kupff er cells in the centrilobular zones. These images, and others not shown, indicate
that virtually all the ZnTCPH was consistently excluded from nuclei of Kupffer cells and from virtually all of the hepatocytes. Little or none remained in extracellular compartments of the liver.

**Microscopic distribution of ZnTCPH in subcutaneous tumors**

The average (macroscopic) boron concentrations in the EMT-6, U-373 and SCCVII tumors shown in Figure 3, frames A, B, and C were 250, 115 and 110 μg/g following injections of 175–210, 180–190 and 350 mg porphyrin/kgbw, respectively. In A, virtually every identifiable cell nucleus (blue) is surrounded by a ring of reddish fluorescence attributable to ZnTCPH. In C, only some nuclei are associated with ZnTCPH fluorescence. Examination of these sections (and of many others not shown) indicates that ZnTCPH-derived fluorescence in tumors was only cytoplasmic and irregularly variable in distribution and intensity, unlike the repeatedly concentric lobular regularity of fluorescence seen microscopically by low-power magnification of liver sections. Further CFM images confirmed the cytoplasmic localization of ZnTCPH: Every zone of ZnTCPH fluorescence in a section of U-373 tumor (Figure 3B) was within a zone of DiO fluorescence visualized under different staining/optical filtration in a congruent section (Figure 3D), although the converse was not true. Our observations also showed that, in the EMT-6 and SCCVII tumors, almost every zone of tumor had some cells with finely punctate cytoplasmic fluorescence compatible with an origin in ZnTCPH-loaded organelles. However, the U373 tumor, which originated from a human glioblastoma, had only scattered zones of such fluorescence, which is compatible with focally occlusive endothelial hyperplasia associated with scattered infarction, which is characteristic of glioblastoma tissue.

**Discussion**

10B-enriched CuTCPH-based BNCT was shown to be effective in locally controlling ~70% of EMT-6 carcinomas implanted in the thighs of mice using a porphyrin dose of 190 μg/gbw, which produced average tumor boron concentrations of 85 μg/g wet tissue (Miura et al. 2001). The average total radiation dose absorbed by tumor was 66 Gy, of which the beam only (i.e., boron-free) radiation dose was only 6 Gy. Similar tumor control was achieved using lower tumor doses (35–42 Gy) of 100 kVp X-rays, but with greater damage to the surrounding normal tissues (Miura et al. 2001). The compound biological effectiveness (CBE) factor is a weighting factor for the boron

![Figure 3. Microdistribution of ZnTCPH in TO-PRO-3-counterstained (for nuclei) sections of several malignant tumors: (A) A murine EMT-6 mammary carcinoma; (C) a murine SCCVII squamous cell carcinoma; (B & D) congruent sections of the U373 glioma. (D), counterstained with DiO for cytoplasm. This Figure is reproduced in color in the online version of International Journal of Radiation Biology.](image-url)
neutron dose component in BNCT, a function of the RBE of the induced alpha particles and lithium ions modulated by the micro-distribution of the boron in the targeted tissues during irradiation. It can be considered analogous to the term relative biological effectiveness [RBE] weighting factor used for the other dose components in this mixed field irradiation (Morris et al. 1994). Because the absorbed radiation dose required to locally control EMT-6 tumors with X-rays is \(-40\) Gy and the total absorbed radiation dose using \(^{10}\)B-CuTCPH-mediated BNCT for similar level of control is \(66\) Gy, it is speculated that the CBE factor for this tumor in this formulation is less than one (Miura et al. 2001). In contrast, the CBE factor for the BPA-fructose complex in a very different tumor model, rats bearing 9L gliosarcomas (in vivo irradiation with in vitro assay), was 1.2 or 1.5, depending on how it was injected (Morris et al. 2002). Moreover, a study using secondary ion mass spectroscopy (SIMS) in rat brain tissues indicated that BPA (shown by in vitro studies to be taken up into tumor cells via an amino acid transporter) is homogeneously distributed in rat gliosarcoma 9LGS cells throughout the cytoplasm and nucleus (Bennett et al. 1994). In contrast, the CFM images presented in this manuscript show that ZnTCPH is distributed heterogeneously throughout the cytoplasm (not the nucleus) of many, but not all EMT-6 carcinoma cells, which is consistent with its lower CBE factor.

The distribution patterns of ZnTCPH fluorescence in the cytoplasm of SCCVII and U373 subcutaneous tumors are similarly heterogeneous. Whether these porphyrins accumulated in the macrophages of these tumors (Kawabata et al. 2011b) as well as in their parenchymal cells was not determined in this study; low-magnification patterns of cell nuclei in the tumors suggested that the preponderance of cells were neoplastic. The preferential localization of the porphyrin in Kupffer cells rather than in hepatocytes in liver is consistent with observations of much lower toxicity from CuTCPH in mice than from some other porphyrins (Miura et al. 1996, 1998). Two days after administration of CuTCPH to mice, even at doses as high as 400 mg CuTCPH/kgbw, neither the weight losses nor the serum levels of hepatic enzymes alanine transaminase (ALT) and aspartate transaminase (AST) were significantly different from those in similar mice given excipient only (Miura et al. 2001), indicative of minimal or no hepatocellular toxicity. Although lipophilic porphyrin clearance is generally thought to be biliary, the green autofluorescence of the gallbladder (Figure 1D, right) suggests that little or none of the liver’s ZnTCPH is excreted in the bile. This is consistent with the preferential localization of red fluorescence in Kupffer cells, with none evident in hepatocytes, the liver cells from which bile originates. That the fluorescence had a mainly portal distribution among Kupffer cells suggests that ZnTCPH was avidly removed from the blood during its first pass through the portal blood circulation, which is compatible with its intraperitoneal injection. If injected intravenously, we posit, a more uniform histologic distribution of red cytoplasmic fluorescence might be observed among Kupffer cells. No overt toxicity was evinced in mice injected by ZnTCPH or CuTCPH at any dose likely to be therapeutically relevant, but their toxicities were not studied past one week after injection (Miura et al. 2001).

However, 4 months and one year after 400 mg CuTCPBr/kgbw was injected into normal BALB/c mice, there were no differences with regard to weight changes, platelet counts and liver enzyme concentrations between the CuTCPBr-injected mice and control mice concomitantly injected with excipient (M. Miura et al., unpublished data).

Compared with BPA, the boronated compound most often used currently for clinical BNCT, extraordinarily high average tumor concentrations of CuTCPH have been achieved. Our short-term studies show that doses of CuTCPH up to 400 mg/kgbw are well tolerated in mice, but long-term studies are lacking. Based on the microdistribution revealed in this study of ZnTCPH, we suggest that BNCT might be implemented more effectively by using a combination of a lipophilic porphyrin such as CuTCPH and a uniformly distributed \(^{10}\)B-enriched boron compound such as BPA. BPA has less affinity than CuTCPH for the tumor types studied herein, but is relatively more uniformly distributed in two types of intracranial rat gliosarcomas (Smith et al. 2001). Since cytotoxic bystander effects (Kashino et al. 2009) extend the tumor-inhibiting effectiveness of radiation-induced free radicals beyond their scattered microscopic zones of origin in a tumor, BNCT based in part on a lipophilic porphyrin such as CuTCPH and in part on BPA might enable palliation of a wider variety of malignancies than is currently feasible; further studies are warranted.

CuTCPBr has been able to enhance the effects of X-irradiation of tumors in mice (Miura et al., 2012). It is expected that CuTCPH would not be as effective due to the lower reduction potential – i.e., from the lack of the electron withdrawing substituents on its macrocycle.

Conclusions

The fluorescent porphyrin ZnTCPH appears to be a useful experimental surrogate for CuTCPH, a potential boron carrier for BNCT. CFM of ZnTCPH indicated a heterogeneous distribution of porphyrin in tumor cells and a uniform one in liver. Preferential cytoplasmic localization of both porphyrins would largely explain why local control of mouse tumors required such high concentrations of CuTCPH-boron.

Acknowledgements

We gratefully acknowledge advice and assistance from Jason Kirk, Susan Krueger, Xiafeng Li, John H. Carson, and Michael S. Makar. We thank Dr Sara C. Rockwell and Dr J. Martin Brown for providing the EMT-6 and SCCVII cell lines, respectively. We are also grateful to the reviewers and editor for their helpful comments.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This work was supported by the Office of Biological and Environmental Research of the U.S. Department of Energy under Contract DE-AC02-98CH10986.
References